Dr. Lisa Anderson, CEO, President and co-founder of Paragonix Technologies, Inc., a company delivering a new standard in organ preservation and transport, discusses a new research study called GUARDIAN-LUNG (Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs) to look at lung preservation and how the way the organ is preserved and transported impact the success of the transplant.
Dr. Lisa Anderson is the Chief Executive Officer, President & Co-Founder of Paragonix Technologies, Inc. Dr. Anderson co-founded Paragonix with a goal to create a new standard of care for organ preservation and transport that would improve patient outcomes worldwide. The result of this initiative has been the development of novel medical devices which provide a sterile, temperature and pressure-controlled environment for organs traveling between operating rooms. Paragonix Technologies has established itself as a global leader in donor organ preservation and transport, and is now utilized at Transplant Centers across the globe. Prior to Paragonix, Dr. Anderson held the position of Vice President at Seed-One Ventures and was an Instructor at Harvard Medical School. Dr. Anderson earned her Ph.D. from Gonsville & Caius College at the University of Cambridge. Additionally, Dr. Anderson completed Postdoctoral fellowships at the Cambridge Institute for Medical Research at the University of Cambridge and Harvard Medical School.